- Coordinates
- PDB Format
- Method
- X-RAY DIFFRACTION 2.80 Å
- Oligo State
- homo-dimer
- Ligands
- 2 x BF0: methyl 4-{[(5beta,6alpha)-17-(cyclopropylmethyl)-3,14-dihydroxy-4,5-epoxymorphinan-6-yl]amino}-4-oxobutanoate(Covalent)
- 24 x SO4: SULFATE ION(Non-functional Binders)
SO4.2: 6 residues within 4Å:- Chain A: T.50, A.51, T.52, R.114, R.128, I.381
Ligand excluded by PLIPSO4.3: 4 residues within 4Å:- Chain A: N.86, K.90, A.155, T.156
Ligand excluded by PLIPSO4.4: 7 residues within 4Å:- Chain A: H.120, P.121, V.122, K.123, R.219, G.223, L.224
Ligand excluded by PLIPSO4.5: 3 residues within 4Å:- Chain A: R.225, L.226, K.227
Ligand excluded by PLIPSO4.6: 4 residues within 4Å:- Chain A: H.172, P.173, T.174, W.175
Ligand excluded by PLIPSO4.7: 6 residues within 4Å:- Chain A: G.324, F.325, T.326, N.327, S.328, N.343
Ligand excluded by PLIPSO4.8: 2 residues within 4Å:- Chain A: S.347, R.348
Ligand excluded by PLIPSO4.9: 2 residues within 4Å:- Chain A: R.330, Q.334
Ligand excluded by PLIPSO4.10: 2 residues within 4Å:- Chain A: R.380, R.383
Ligand excluded by PLIPSO4.11: 5 residues within 4Å:- Chain A: H.120, R.207, R.219, L.224, K.271
Ligand excluded by PLIPSO4.12: 4 residues within 4Å:- Chain A: T.353, P.354, N.355, R.356
Ligand excluded by PLIPSO4.13: 3 residues within 4Å:- Chain A: R.44, Y.45, T.46
Ligand excluded by PLIPSO4.20: 6 residues within 4Å:- Chain B: T.50, A.51, T.52, R.114, R.128, I.381
Ligand excluded by PLIPSO4.21: 4 residues within 4Å:- Chain B: N.86, K.90, A.155, T.156
Ligand excluded by PLIPSO4.22: 7 residues within 4Å:- Chain B: H.120, P.121, V.122, K.123, R.219, G.223, L.224
Ligand excluded by PLIPSO4.23: 3 residues within 4Å:- Chain B: R.225, L.226, K.227
Ligand excluded by PLIPSO4.24: 4 residues within 4Å:- Chain B: H.172, P.173, T.174, W.175
Ligand excluded by PLIPSO4.25: 6 residues within 4Å:- Chain B: G.324, F.325, T.326, N.327, S.328, N.343
Ligand excluded by PLIPSO4.26: 2 residues within 4Å:- Chain B: S.347, R.348
Ligand excluded by PLIPSO4.27: 2 residues within 4Å:- Chain B: R.330, Q.334
Ligand excluded by PLIPSO4.28: 2 residues within 4Å:- Chain B: R.380, R.383
Ligand excluded by PLIPSO4.29: 5 residues within 4Å:- Chain B: H.120, R.207, R.219, L.224, K.271
Ligand excluded by PLIPSO4.30: 4 residues within 4Å:- Chain B: T.353, P.354, N.355, R.356
Ligand excluded by PLIPSO4.31: 3 residues within 4Å:- Chain B: R.44, Y.45, T.46
Ligand excluded by PLIP- 2 x CLR: CHOLESTEROL(Non-covalent)
CLR.14: 8 residues within 4Å:- Chain A: T.397, P.398, I.401, Y.402, I.405, I.411, F.416, S.420
8 PLIP interactions:8 interactions with chain A- Hydrophobic interactions: A:T.397, A:P.398, A:I.401, A:Y.402, A:Y.402, A:I.405, A:I.411, A:F.416
CLR.32: 8 residues within 4Å:- Chain B: T.397, P.398, I.401, Y.402, I.405, I.411, F.416, S.420
8 PLIP interactions:8 interactions with chain B- Hydrophobic interactions: B:T.397, B:P.398, B:I.401, B:Y.402, B:Y.402, B:I.405, B:I.411, B:F.416
- 4 x MPG: [(Z)-octadec-9-enyl] (2R)-2,3-bis(oxidanyl)propanoate(Non-covalent)
MPG.15: 5 residues within 4Å:- Chain A: F.57, N.58, K.134, N.137, W.141
8 PLIP interactions:8 interactions with chain A- Hydrophobic interactions: A:F.57, A:N.137, A:W.141, A:W.141, A:W.141
- Hydrogen bonds: A:K.134
- Salt bridges: A:K.49, A:K.134
MPG.16: 8 residues within 4Å:- Chain A: M.21, Y.24, S.25, C.28, L.32, L.70, P.71, S.74
5 PLIP interactions:5 interactions with chain A- Hydrophobic interactions: A:L.32, A:P.71
- Hydrogen bonds: A:M.21, A:Y.24, A:S.74
MPG.33: 5 residues within 4Å:- Chain B: F.57, N.58, K.134, N.137, W.141
8 PLIP interactions:8 interactions with chain B- Hydrophobic interactions: B:F.57, B:N.137, B:W.141, B:W.141, B:W.141
- Hydrogen bonds: B:K.134
- Salt bridges: B:K.49, B:K.134
MPG.34: 8 residues within 4Å:- Chain B: M.21, Y.24, S.25, C.28, L.32, L.70, P.71, S.74
5 PLIP interactions:5 interactions with chain B- Hydrophobic interactions: B:L.32, B:P.71
- Hydrogen bonds: B:M.21, B:Y.24, B:S.74
- 2 x 1PE: PENTAETHYLENE GLYCOL(Non-functional Binders)
1PE.17: 13 residues within 4Å:- Chain A: W.175, K.406, A.407, L.408, I.409, T.410
- Chain B: W.175, K.406, A.407, L.408, I.409, T.410
- Ligands: 1PE.35
1 PLIP interactions:1 interactions with chain A- Hydrogen bonds: A:K.406
1PE.35: 13 residues within 4Å:- Chain A: W.175, K.406, A.407, L.408, I.409, T.410
- Chain B: W.175, K.406, A.407, L.408, I.409, T.410
- Ligands: 1PE.17
1 PLIP interactions:1 interactions with chain B- Hydrogen bonds: B:K.406
- 2 x CL: CHLORIDE ION(Non-functional Binders)
- Links
- RCSB PDBe PDBe-KB PDBj PDBsum CATH PLIP
- Citation
- Manglik, A. et al., Crystal structure of the {mu}-opioid receptor bound to a morphinan antagonist. Nature (2012)
- Release Date
- 2012-03-21
- Peptides
- Mu-type opioid receptor, lysozyme chimera: AB
- SMTL:PDB
- SMTL Chain Id:
PDB Chain Id:A
AB
A - Membrane
-
We predict this structure to be a membrane protein.
- Coordinates
- PDB Format
- Method
- X-RAY DIFFRACTION 2.80 Å
- Oligo State
- homo-dimer
- Ligands
- 2 x BF0: methyl 4-{[(5beta,6alpha)-17-(cyclopropylmethyl)-3,14-dihydroxy-4,5-epoxymorphinan-6-yl]amino}-4-oxobutanoate(Covalent)
- 24 x SO4: SULFATE ION(Non-functional Binders)
- 2 x CLR: CHOLESTEROL(Non-covalent)
- 4 x MPG: [(Z)-octadec-9-enyl] (2R)-2,3-bis(oxidanyl)propanoate(Non-covalent)
- 2 x 1PE: PENTAETHYLENE GLYCOL(Non-functional Binders)
- 2 x CL: CHLORIDE ION(Non-functional Binders)
- Links
- RCSB PDBe PDBe-KB PDBj PDBsum CATH PLIP
- Citation
- Manglik, A. et al., Crystal structure of the {mu}-opioid receptor bound to a morphinan antagonist. Nature (2012)
- Release Date
- 2012-03-21
- Peptides
- Mu-type opioid receptor, lysozyme chimera: AB
- SMTL:PDB
- SMTL Chain Id:
PDB Chain Id:A
AB
A - Membrane
-
We predict this structure to be a membrane protein.